557 reports of this reaction
2.4% of all VEMURAFENIB reports
#10 most reported adverse reaction
ALOPECIA is the #10 most commonly reported adverse reaction for VEMURAFENIB, manufactured by Genentech, Inc.. There are 557 FDA adverse event reports linking VEMURAFENIB to ALOPECIA. This represents approximately 2.4% of all 23,551 adverse event reports for this drug.
Patients taking VEMURAFENIB who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a less commonly reported adverse event for VEMURAFENIB, but still significant enough to appear in the safety profile.
In addition to alopecia, the following adverse reactions have been reported for VEMURAFENIB:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 557 FDA reports for VEMURAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 2.4% of all adverse event reports for VEMURAFENIB, making it a notable side effect.
If you experience alopecia while taking VEMURAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.